Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Tsutomu Takeuchi, Yoshiya Tanaka, Mitsuhiro Rokuda, Hiroyuki Izutsu, Yuichiro Kaneko, Musashi Fukuda & Daisuke Kato. (2021) A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. Modern Rheumatology 31:3, pages 543-555.
Read now
Read now
Masayoshi Harigai, Tsutomu Takeuchi, Josef S. Smolen, Kevin L. Winthrop, Atsushi Nishikawa, Terence P. Rooney, Chadi G. Saifan, Maher Issa, Yoshitaka Isaka, Naotsugu Akashi, Taeko Ishii & Yoshiya Tanaka. (2020) Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. Modern Rheumatology 30:1, pages 36-43.
Read now
Read now
Hisashi Yamanaka, Tomohiro Hirose, Yutaka Endo, Noriko Sugiyama, Yuri Fukuma, Yosuke Morishima, Naonobu Sugiyama, Noritoshi Yoshii, Nobuyuki Miyasaka & Takao Koike. (2019) Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan: Results of long-term postmarketing surveillance. Modern Rheumatology 29:5, pages 737-746.
Read now
Read now
Articles from other publishers (15)
B. S. Belov & N. V. Muravyeva. (2023) Modern Ideas about Vaccination of Patients with Rheumatic Diseases: the View of ACR Experts. Antibiotics and Chemotherapy 68:5-6, pages 77-83.
Crossref
Crossref
Masataka Kuwana, Naonobu Sugiyama, Shigeki Momohara, Tatsuya Atsumi, Syuji Takei, Naoto Tamura, Masayoshi Harigai, Takao Fujii, Hiroaki Matsuno, Tsutomu Takeuchi, Kazuhiko Yamamoto, Yoshinari Takasaki, Miki Tanigawa, Yutaka Endo, Tomohiro Hirose, Yosuke Morishima, Noritoshi Yoshii, Tsuneyo Mimori & Michiaki Takagi. (2023) Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance. Modern Rheumatology.
Crossref
Crossref
Sithembiso Tiyandza Dlamini, Kyaw Moe Htet, Ei Chue Chue Theint, Aerrosa Murenda Mayadilanuari, Wei-Ming Li, Yi-Ching Tung & Hung-Pin Tu. (2023) Herpes Zoster Risk in Patients with Rheumatoid Arthritis and Its Association with Medications Used. International Journal of Environmental Research and Public Health 20:3, pages 2123.
Crossref
Crossref
Rei Yamaguchi, Eiichi Tanaka, Ayako Nakajima, Eisuke Inoue, Mai Abe, Eri Sugano, Naohiro Sugitani, Kumiko Saka, Moeko Ochiai, Yoko Higuchi, Naoki Sugimoto, Katsunori Ikari, Hisashi Yamanaka & Masayoshi Harigai. (2022) Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids. Modern Rheumatology 32:3, pages 522-527.
Crossref
Crossref
Jiahui Qian, Marissa Nichole Lassere, Anita Elizabeth Heywood & Bette Liu. (2021) Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults. Rheumatology 60:11, pages 5042-5051.
Crossref
Crossref
Jiahui Qian, Emily Banks, Kristine Macartney, Anita Elizabeth Heywood, Marissa Nichole Lassere & Bette Liu. (2021) Corticosteroid Use and Risk of Herpes Zoster in a Population-Based Cohort. Mayo Clinic Proceedings 96:11, pages 2843-2853.
Crossref
Crossref
Keiko Tanaka, Eizen Kimura, Kensuke Oryoji, Shin-ichi Mizuki, Tomoko Kobayashi, Atsushi Nishikawa, Eiko Yoshinaga & Yoshihiro Miyake. (2021) Hypertension and dyslipidemia are risk factors for herpes zoster in patients with rheumatoid arthritis: a retrospective analysis using a medical information database. Rheumatology International 41:9, pages 1633-1639.
Crossref
Crossref
Elisa Gremese, Stefano Alivernini, Barbara Tolusso, Martin P Zeidler & Gianfranco Ferraccioli. (2019) JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. Journal of Leukocyte Biology 106:5, pages 1063-1068.
Crossref
Crossref
Victoria Furer, Christien Rondaan, Marloes Heijstek, Sander van Assen, Marc Bijl, Nancy Agmon-Levin, Ferdinand C Breedveld, Raffaele D'Amelio, Maxime Dougados, Meliha Crnkic Kapetanovic, Jacob M van Laar, Annette Ladefoged de Thurah, Robert Landewé, Anna Molto, Ulf Müller-Ladner, Karen Schreiber, Leo Smolar, Jim Walker, Klaus Warnatz, Nico M Wulffraat & Ori Elkayam. (2019) Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 5:2, pages e001041.
Crossref
Crossref
Eun Bong Lee, Hisashi Yamanaka, Yi Liu, Wen‐Chan Tsai, Connie Chen, Kenneth Kwok, Hyun–Jeong Yoo, Lyndon J. Llamado, Lisy Wang, Yingchun Luo, Naonobu Sugiyama & Yoshiya Tanaka. (2019) Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia‐Pacific region: Post‐hoc analyses of pooled clinical study data. International Journal of Rheumatic Diseases 22:6, pages 1094-1106.
Crossref
Crossref
Ryoko Sakai, Shoko Kasai, Fumio Hirano, Sayoko Harada, Mari Kihara, Waka Yokoyama, Michi Tsutsumino, Kenji Nagasaka, Ryuji Koike, Hisashi Yamanaka, Nobuyuki Miyasaka & Masayoshi Harigai. (2018) No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database. International Journal of Rheumatic Diseases 21:9, pages 1670-1677.
Crossref
Crossref
Sayoko Harada, Ryoko Sakai, Fumio Hirano, Nobuyuki Miyasaka & Masayoshi Harigai. (2017) Association Between Medications and Herpes Zoster in Japanese Patients with Rheumatoid Arthritis: A 5-year Prospective Cohort Study. The Journal of Rheumatology 44:7, pages 988-995.
Crossref
Crossref
Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi, Naonobu Sugiyama, Hirotoshi Yuasa, Shigeyuki Toyoizumi, Yosuke Morishima, Tomohiro Hirose & Samuel Zwillich. (2016) Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Research & Therapy 18:1.
Crossref
Crossref
Fawziah Marra, Elaine Lo, Viktor Kalashnikov & Kathryn Richardson. (2016) Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases 3:4.
Crossref
Crossref
Kunihiro YAMAOKA. (2016) Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis. Japanese Journal of Clinical Immunology 39:3, pages 181-189.
Crossref
Crossref